Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.

Trial Profile

Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2015

At a glance

  • Drugs Azithromycin (Primary) ; Tobramycin
  • Indications Bacterial infections; Infectious conjunctivitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Laboratoires Thea
  • Most Recent Events

    • 28 Apr 2012 Additional trial locations identified as reported by European Clinical Trials Database.
    • 28 Apr 2012 Planned number of patients changed from 222 to 444 as reported by European Clinical Trials Database.
    • 09 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top